NCT04883996Unknown1 期
A Phase 1/2, Randomized, Placebo Controlled Crossover Study to Assess the Safety, Pharmacodynamics, and Efficacy of EXP039 Ophthalmic Solution in Participants With Myopia or Hyperopia
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- UDVA
研究概览
简要总结
Assess the Safety, Pharmacodynamics, and Efficacy of EXP039 Ophthalmic Solution in Participants with Myopia or Hyperopia
详细描述
To characterize the effect of pupillary miosis as achieved with EXP039 1% ophthalmic solution in terms of mean number of lines (Early Treatment Diabetic Retinopathy Study [ETDRS]) of improvement from baseline in binocular (both eyes open) mesopic high-contrast uncorrected distance visual acuity (UDVA) at 1-hour post treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age ≥18 to ≤80 years
- •Participants must be in good general health, with no significant medical problems that, in the opinion of the investigator, would preclude participation in the trial, at Screening and/or before administration of the dose of study drug
- •Low-to-moderate hyperopia (SER of +0.50D to +2.00D) or myopia (SER of -0.50 D to -4.00D) at Screening
- •Between-eye SER difference of no more than 0.50D
- •Best-corrected distance visual acuity better than or equal to 20/20 in both eyes at Screening
- •Astigmatism in each eye of less than or equal to 0.75D with manifest refraction at Screening
- •Women of childbearing potential (WOCBP) must have a negative urine pregnancy test at Screening
- •WOCBP must be non-pregnant and non-lactating, and must use a medically approved, highly effective contraception method from Screening until study completion, including the follow up period. Female participants who are in same sex relationships are not required to use contraception.Males must be surgically sterile (>30 days since vasectomy with no viable sperm), abstinent, or if engaged in sexual relations with a WOCBP, the participant and his partner must use a medically approved, highly effective contraceptive method from Screening until study completion, including the follow-up period.
- •Males must not donate sperm for at least 90 days after the last dose of study drug
- •Participants must have the ability and willingness to attend the necessary visits
- •Participants must be willing and able to provide written informed consent after the nature of the study has been explained and prior to the commencement of any study procedures.
排除标准
- •Any central corneal abnormality (e.g., keratoconus, Pellucid marginal degeneration, corneal scar, Fuchs' endothelial dystrophy, guttata, or edema) in either eye that is likely to interfere with visual acuity
- •Moderate or severe dry eye as defined by corneal fluorescein staining score of ≥3 on Oxford scale at Screening
- •Any clinically significant pupillary or iris abnormality (e.g., anisocoria of >1 mm between eyes at Screening or baseline, abnormal pupil shape in either eye, iris transillumination defects, or any congenital or traumatic defect of the iris)
- •Narrow iridocorneal angles (Shaffer grade ≤2 or lower on gonioscopy examination), history of angle-closure glaucoma, or previous iridotomy
- •Intraocular pressure (IOP) <8 mmHg or >23 mmHg in either eye or history of glaucoma or ocular hypertension
- •Any clinically significant abnormal lens finding (e.g., cataract, loose zonules, exfoliation, pseudoexfoliation)
- •History of any intraocular surgery including cataract surgery or phakic intraocular lens surgery
- •History in either eye of previous corneal inlay, full- or partial-thickness corneal transplant, radial keratotomy or any corneal surgery including laser-based corneal refractive surgery
- •Any clinically significant abnormal finding on dilated fundus examination in either eye or known history of retinal detachment, retinal trauma, retinal or vitreal surgery, or clinically significant retinal disease in either eye
- •Clinically significant strabismus or diplopia
- •History of stereo vision difficulties
- •History of optic neuropathy or amblyopia in either eye
- •Use of orthokeratology contact lenses within the past 1 month prior to EXP039 dosing on Day 1
- •Use of temporary or permanent punctal plugs or history of punctal cautery in one or both eyes
- •Planned use of any contact lenses during the study
- •Allergy to pilocarpine or any of its excipients
- •Serious systemic illness that, in the opinion of the Investigator's, would render the participant ineligible
- •Pre-planned hospitalization or ocular or systemic surgery during the study period
- •History of any substance abuse (alcohol and/or illegal drugs) and not willing to abstain from drug(s) and reasonably limit alcohol consumption to approximately 2 alcoholic beverages per day during the 30-day study period
- •Participation in any other study of investigational therapy during the study period or within the last 30 days or 5 half-lives, whichever is longer
- •Unwilling or unable to complete study procedures or to be followed up for the duration of the study
研究组 & 干预措施
EXP039
Active Comparator
At Visit 1, single dose 1 drop of EXP039 1% is adminstered, followed by washout period of 1-10 days. Subsequently, subjects will crossover to single dose 1 drop saline at Visit 2.
干预措施: 1% EXP039 (Drug)
Saline control
Placebo Comparator
At Visit 1, single dose 1 drop of saline is adminstered, followed by washout period of 1-10 days. Subsequently, subjects will crossover to single dose 1 drop EXP039 1% at Visit 2.
干预措施: Saline control (Other)
结局指标
主要结局
UDVA
时间窗: 1 hour
Mesopic high-contrast uncorrected distance visual acuity
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Evaluate the Safety and Efficacy of EV06 Ophthalmic Solution in Improving Vision in Subjects With PresbyopiaPresbyopiaNCT02516306Encore Vision, Inc.75
已完成
2 期
Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry EyeDry Eye DiseaseNCT04268069ORA, Inc.160
已完成
3 期
Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired BlepharoptosisAcquired BlepharoptosisNCT02436759RVL Pharmaceuticals, Inc.140
终止
2 期
A Study Assessing Efficacy and Safety of OC-10X in the Treatment of PDRProliferative Diabetic Retinopathy (PDR)NCT02735369OcuCure Therapeutics, Inc.40
已完成
3 期
Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)Dry Eye Disease (DED)NCT04139798Bausch & Lomb Incorporated599